Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026)

Surrozen (SRZN) recorded quarterly Total Non-Current Liabilities of $249.9 million in Q1 2026, up 43.69% quarter-over-quarter from $173.9 million in Q4 2025, and up 274.53% on a YoY basis from $66.7 million in Q1 2025.

Surrozen (SRZN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Surrozen's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $249.9 million for Q1 2026.

  • In Q1 2026, Total Non-Current Liabilities rose 274.53% year-over-year to $249.9 million; the TTM figure through Mar 2026 stood at $249.9 million (up 274.53% YoY), while the FY2025 annual figure was $173.9 million, up 149.03% from the prior year.
  • Total Non-Current Liabilities was $249.9 million for Q1 2026 at Surrozen, up from $173.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $249.9 million in Q1 2026 to a low of $6.0 million in Q2 2024.
  • Historically, Total Non-Current Liabilities has averaged $44.3 million across 5 years, with a median of $13.0 million in 2022.
  • The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slumped 39.44% in 2024, then surged 946.03% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $13.1 million in 2022, then tumbled by 38.74% to $8.0 million in 2023, then jumped by 769.83% to $69.8 million in 2024, then surged by 149.03% to $173.9 million in 2025, then surged by 43.69% to $249.9 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $249.9 million (Q1 2026), $173.9 million (Q4 2025), and $64.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - 42,980.09
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - 11.03 Mn
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 95.20 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - 644,700.00
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 5.87 Bn
9 Abivax 94.37 Bn 94.37 Bn - 64.76 Mn
10 Surrozen 225,877.86 -106.68 Mn - 249.93 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 249.93 Mn
Dec 31, 2025 173.94 Mn
Sep 30, 2025 64.02 Mn
Jun 30, 2025 22.96 Mn
Mar 31, 2025 66.73 Mn
Dec 31, 2024 69.85 Mn
Sep 30, 2024 6.12 Mn
Jun 30, 2024 5.98 Mn
Mar 31, 2024 6.40 Mn
Dec 31, 2023 8.03 Mn
Sep 30, 2023 8.20 Mn
Jun 30, 2023 8.62 Mn
Mar 31, 2023 10.57 Mn
Dec 31, 2022 13.11 Mn
Sep 30, 2022 12.61 Mn
Jun 30, 2022 13.05 Mn
Mar 31, 2022 13.19 Mn
Dec 31, 2021 19.17 Mn
Sep 30, 2021 18.60 Mn
Jun 30, 2021 4.76 Mn